Clinical Findings and Presentations, Increased Quarterly Dividends, Conference Call Schedules, and Accrued Interest on Zero

Clinical Findings and Presentations, Increased Quarterly Dividends, Conference
 Call Schedules, and Accrued Interest on Zero Coupon Notes - Analyst Notes on
                 Amgen, Zimmer, Covidien, LabCorp, and Enanta

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, March 19, 2014

NEW YORK, March 19, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Amgen, Inc.
(NASDAQ: AMGN), Zimmer Holdings, Inc. (NYSE: ZMH), Covidien plc (NYSE: COV),
Laboratory Corporation of America Holdings (NYSE: LH), and Enanta
Pharmaceuticals, Inc. (NASDAQ: ENTA). Private wealth members receive these
notes ahead of publication. To reserve complementary membership, limited
openings are available at:


On March 14, 2014, Amgen, Inc. (Amgen) announced findings from a pre-specified
retrospective analysis of patients with metastatic melanoma. The findings
showed that talimogene laherparepvec has reduced the size of injected tumors
and also non-injected tumors that had metastasized to other parts of the body.
The Company reported that the analysis recorded tumor-level responses from a
pivotal Phase 3 study evaluating talimogene laherparepvec in patients with
injectable unresected stage IIIB, IIIC, or IV melanoma compared to
granulocyte-macrophage colony-stimulating factor (GM-CSF). "These data add to
the body of evidence supporting talimogene laherparepvec's local and distant
effect, and its potential ability to stimulate a systemic anti-tumor immune
response," said Sean E. Harper, M.D., Executive Vice President of Research and
Development at Amgen. "Melanoma remains a devastating and difficult-to-treat
disease, and talimogene laherparepvec continues to demonstrate encouraging
results in this setting." The full analyst notes on Amgen, Inc. are available
to download free of charge at:


On March 5, 2014, Zimmer Holdings, Inc. (Zimmer) announced that its Board of
Directors has approved an increased quarterly cash dividend for Q1 FY 2014.
The increased dividend of $0.22 per share represents a 10% increase over its
Q1 FY 2013 dividend. The Company informed that the dividend is payable on
April 25, 2014, to stockholders of record as of the close of business on March
28, 2014. The full analyst notes on Zimmer Holdings, Inc. are available to
download free of charge at:


On March 14, 2014, Covidien plc (Covidien) announced that it intends to
release its Q2 FY2014 results on April 25, 2014. The results will be followed
by a conference call for investor, scheduled to be held at 8:30 a.m. ET on the
same day. The call will be accessible throughCovidien's website or by
telephone.Also, an audio replay of the conference call will be available
beginning at 11:30 a.m. ET on April 25, 2014 through 5:00 p.m. ET on May 2,
2014.The full analyst notes on Covidien plc are available to download free of
charge at:


On March 11, 2014, Laboratory Corporation of America Holdings (LabCorp)
announced that its Zero Coupon Convertible Subordinated Notes due 2021 will
accrue contingent cash interest for the period of March 12, 2014 to September
11, 2014, at a rate of no less than 0.125% of the average market price of Zero
Coupon Note for the five trading days ended March 6, 2014. The Company
informed that it has determined the contingent cash interest to be
approximately $1.56 per Note, and is payable to holders of the Zero Coupon
Notes as of the record date of August 27, 2014. LabCorp expects the payment of
the contingent cash interest to take place on September 11, 2014. The full
analyst notes on Laboratory Corporation of America Holdings are available to
download free of charge at:


On March 4, 2014, Enanta Pharmaceuticals, Inc. (Enanta) announced that new in
vitro data on ABT-493, a potent NS3/4 protease inhibitor, was presented at the
21^st Conference on Retroviruses and Opportunistic Infections (CROI) in
Boston. The data presented showed that ABT-493 has a substantially improved in
vitro profile compared to earlier generation HCV NS3/4A protease inhibitors
and displays potent and broad genotypic activity in genotypes 1a, 1b, 2a, 3a,
4a, and 6a, against which many other HCV NS3/4A protease inhibitors have
significantly lower potency. Further, Enanta stated that in vitro ABT-492
retains potency against most of the clinically important resistance-associated
variants in genotype 1 and is fully active against variants resistant to NS5A
or NS5B inhibitors. The full analyst notes Enanta Pharmaceuticals, Inc. are
available to download free of charge at:


We provide our members with a simple and reliable way to leverage our economy
of scale. Most investors do not have time to track all publicly traded
companies, much less perform an in-depth review and analysis of the
complexities contained in each situation. That's where Analysts Review comes
in. We provide a single unified platform for investors' to hear about what
matters. Situation alerts, moving events, and upcoming opportunities.



  oThis is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
  oInformation in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
  oThis information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
  oIf you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at pubco [at]
  oForanyurgentconcernsorinquiries, please contact us at compliance
  oAre you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to research [at] for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Analysts Review. An
outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Analysts Review in this article or
report according to the Procedures outlined by Analysts Review. Analysts
Review is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.


Analysts Review makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to be construed
as personal financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold any
securities mentioned herein.


Analysts Review is not responsible for any error which may be occasioned at
the time of printing of this document or any error, mistake or shortcoming. No
liability is accepted by Analysts Review whatsoever for any direct, indirect
or consequential loss arising from the use of this document. Analysts Review
expressly disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The included
information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA

SOURCE Analysts Review

Contact: Contact: Adam Redford, +852-8191-3972
Press spacebar to pause and continue. Press esc to stop.